Indian Immunologicals produces Covaxin drug substance
The output of Covaxin drug substance will be three-to-four million a month, and from December, will increase to 10 million a month
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Indian Immunologicals
IIL to produce drug substance for Covaxin from June
Plans to dispatch the first batch to Bharat Biotech by July
PSUs roped in to ramp up COVID-19 vaccine production
Few weeks ago, inter-ministerial teams had visited the sites of two main vaccine manufacturers in India to get their inputs on how…
IIL to invest Rs 75 cr for viral antigen manufacturing facility in Telangana
The company also plans to utilise the facility to manufacture COVID-19 vaccines post completion of its R&D with Griffith…
Why COVID-19 presents a golden opportunity to Indian pharma firms
Juilee Dandekar, Sector Expert - Healthcare, Business Research & Advisory, Aranca informs that with India Pharma Inc's…
Seven Indian pharmaceutical companies race to develop vaccine for deadly coronavirus
Bharat Biotech, Serum Institute, Zydus Cadila, Panacea Biotec, Indian Immunologicals, Mynvax and Biological E are among the…
How glass vial makers are girding to boost access to COVID-19 vaccine
Leading glass packaging manufacturers in India disclose their measures to ramp up capacities and support India Pharma Inc as it…
Indian Immunologicals launches classical swine fever vaccine
Called ‘Raksha Class’, this vaccine has been developed in collaboration with Indian Veterinary Research Institute (IVRI), Bareilly
Indian Immunologicals to lead research collaboration to develop vaccine for COVID-19
The company will carry the research in collaboration with Griffith University, Australia
‘Our turnover has grown 65 per cent in comparison to 2015-16. We are looking to grow 40 per…
IIL is a leading manufacturer of human and animal vaccines in India and other global markets. Dr K Anand Kumar, MD, Indian…